1. Home
  2. Browse
  3. Practice
  4. Legal & Licensing
  5. Drug Withdrawals/Restricted Sale

Drug Withdrawals/Restricted Sale

61 - 75 of 143 Results
Sort Results:
Commentary: New Formulation: Combivent Respimat September 2012
Article: supplies of the injectable blood thinner lepirudin (Refludan) dwindle over the next few months August 2012
Chart: Comparison of Injectable Anticoagulants August 2012
Article: avoid mishaps with cough and cold medications November 2011
Article: You'll finally see Primatene Mist (epinephrine) disappear and the new Combivent Respimat appear November 2011
Other: FDA Podcast: Withdrawal of Primatene Mist (April 2011) November 2011
Commentary: Market Withdrawal of Primatene Mist (Epinephrine) Inhalers November 2011
Article: two new opioid formulations, Oxecta and Lazanda October 2011
Chart: Fentanyl Products for Breakthrough Pain October 2011
Commentary: New Formulation: Oxecta (Oxycodone) October 2011
Chart: Drugs with REMS and Other Special Prescribing/Dispensing Requirements October 2011
Article: confusing the news about Avandia and Actos July 2011
Commentary: Actos (Pioglitazone) and Increased Risk of Bladder Cancer July 2011
Article: A new Risk Evaluation and Mitigation Strategy (REMS) will aim to reduce the misuse of long-acting opioid pain meds (OxyContin, etc) June 2011
Commentary: REMS for Long-Acting and Extended-Release Opioids June 2011